HK1043313A1 - 用於治療癌症的多西他賽和rhumab her2 - Google Patents

用於治療癌症的多西他賽和rhumab her2

Info

Publication number
HK1043313A1
HK1043313A1 HK02104971.3A HK02104971A HK1043313A1 HK 1043313 A1 HK1043313 A1 HK 1043313A1 HK 02104971 A HK02104971 A HK 02104971A HK 1043313 A1 HK1043313 A1 HK 1043313A1
Authority
HK
Hong Kong
Prior art keywords
docetaxel
rhumab her2
cancers
treatment
combination
Prior art date
Application number
HK02104971.3A
Other languages
English (en)
Inventor
Le Vogel Charles
E Bellet Robert
Original Assignee
Charles L Vogel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22435924&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1043313(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Charles L Vogel filed Critical Charles L Vogel
Publication of HK1043313A1 publication Critical patent/HK1043313A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Drying Of Gases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
HK02104971.3A 1999-04-09 2002-07-02 用於治療癌症的多西他賽和rhumab her2 HK1043313A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12856499P 1999-04-09 1999-04-09
PCT/US2000/009247 WO2000061185A1 (en) 1999-04-09 2000-04-07 Docetaxel in combination with rhumab her2 for the treatment of cancers

Publications (1)

Publication Number Publication Date
HK1043313A1 true HK1043313A1 (zh) 2002-09-13

Family

ID=22435924

Family Applications (2)

Application Number Title Priority Date Filing Date
HK02104971.3A HK1043313A1 (zh) 1999-04-09 2002-07-02 用於治療癌症的多西他賽和rhumab her2
HK02107549.9A HK1046093B (zh) 1999-04-09 2002-10-17 用於治療癌症的泰素帝和重組人源化her2單克隆抗體的組合

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK02107549.9A HK1046093B (zh) 1999-04-09 2002-10-17 用於治療癌症的泰素帝和重組人源化her2單克隆抗體的組合

Country Status (22)

Country Link
US (1) US6333348B1 (zh)
EP (1) EP1169059B1 (zh)
JP (2) JP2003512298A (zh)
KR (1) KR100695383B1 (zh)
CN (1) CN1191859C (zh)
AT (1) ATE307608T1 (zh)
AU (1) AU777661B2 (zh)
BR (1) BR0009647A (zh)
CA (1) CA2368369C (zh)
CZ (1) CZ296373B6 (zh)
DE (1) DE60023476T2 (zh)
DK (1) DK1169059T3 (zh)
EA (1) EA006097B1 (zh)
ES (1) ES2248070T3 (zh)
HK (2) HK1043313A1 (zh)
HU (1) HU226672B1 (zh)
MX (1) MXPA01010138A (zh)
NO (1) NO332619B1 (zh)
NZ (1) NZ515337A (zh)
TR (1) TR200102845T2 (zh)
WO (1) WO2000061185A1 (zh)
ZA (1) ZA200107771B (zh)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
ES2533255T3 (es) * 1998-07-13 2015-04-08 Board Of Regents, The University Of Texas System Utilización de anticuerpos anti-aminofosfolípidos para el tratamiento del cáncer
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
WO2000002587A1 (en) * 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
JP4579471B2 (ja) * 1999-06-25 2010-11-10 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
GB9917012D0 (en) * 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
KR20090024308A (ko) * 1999-08-27 2009-03-06 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
JP2003534292A (ja) 2000-05-19 2003-11-18 ジェネンテック・インコーポレーテッド Ｅｒｂｂアンタゴニスト癌治療に対する有効な応答の可能性を向上させるための遺伝子検出アッセイ
WO2002041914A1 (en) * 2000-11-21 2002-05-30 Cell Pathways, Inc. Method for treating neoplasia by administering an anti-her2 antibody and a cgmp-specific phosphodiesterase inhibitor
EP1353693B1 (en) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
PT2762140T (pt) 2001-02-19 2017-07-04 Novartis Ag Resumo
WO2002087629A1 (en) * 2001-04-26 2002-11-07 Analogic Corporation Ct scanner for imaging a preselected portion of a patient
US7452539B2 (en) * 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
GB0200657D0 (en) * 2002-01-12 2002-02-27 Antisoma Plc Cancer treatment
US7247303B2 (en) * 2002-07-15 2007-07-24 Board Of Regents, The University Of Texas System Selected antibody CDRs for binding to aminophospholipids
US7622118B2 (en) * 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7678386B2 (en) 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US7625563B2 (en) * 2002-07-15 2009-12-01 Board Of Regents, The University Of Texas System Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
US7572448B2 (en) * 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Combined cancer treatment methods using selected antibodies to aminophospholipids
CN104225610B (zh) * 2002-07-15 2017-03-01 得克萨斯大学体系董事会 与阴离子磷脂和氨基磷脂结合的选定抗体及其治疗用途
US7615223B2 (en) * 2002-07-15 2009-11-10 Board Of Regents, The University Of Texas System Selected immunoconjugates for binding to aminophospholipids
US7714109B2 (en) * 2002-07-15 2010-05-11 Board Of Regents, The University Of Texas System Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
JP2006516117A (ja) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
KR20130089280A (ko) 2005-01-21 2013-08-09 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
CA2595395A1 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting her2 shedding with matrix metalloprotease antagonists
MY152164A (en) 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
WO2007038792A2 (en) * 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
EP1913958B1 (en) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab
FR2904782B1 (fr) * 2006-08-11 2008-10-31 Delta Proteomics Soc Par Actio Co-colloides supramoleculaires obtenus a l'aide de systemes macrocycliques polyanioniques
BRPI0808418A2 (pt) 2007-03-02 2014-07-22 Genentech Inc Predição de resposta a um inibidor de her
DK2171090T3 (da) 2007-06-08 2013-06-10 Genentech Inc Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2133433A1 (en) * 2008-06-09 2009-12-16 Centre Georges François Leclerc A method for predicting responsiveness to a treatment with an anti-HER2 antibody
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010061269A2 (en) * 2008-11-02 2010-06-03 Optimata Ltd. Improving cancer therapy by docetaxel and granulocyte colony-stimulating factor (g-csf)
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
CN102356092B (zh) 2009-03-20 2014-11-05 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
RU2587619C2 (ru) 2010-02-18 2016-06-20 Дженентек, Инк. Антагонисты неурегулина и применение их в лечении злокачественного новообразования
WO2011139172A1 (en) 2010-05-06 2011-11-10 Goran Milosavljevic Diterpene compounds with antineoplastic activities and pharmaceutical compositions comprising same
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2744824A1 (en) 2011-08-17 2014-06-25 F.Hoffmann-La Roche Ag Neuregulin antibodies and uses thereof
MX357759B (es) * 2011-09-01 2018-07-24 Vascular Biogenics Ltd Formulaciones y formas de dosificacion de fosfolipidos oxidados.
CN102321175B (zh) * 2011-09-21 2013-08-07 天津胜发生物技术有限公司 针对乳腺癌Her2/new的纳米抗体或多肽
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
SG11201402510TA (en) 2011-11-30 2014-06-27 Genentech Inc Erbb3 mutations in cancer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
EP2831115A1 (en) 2012-03-27 2015-02-04 F. Hoffmann-La Roche AG Diagnosis and treatments relating to her3 inhibitors
US9308235B2 (en) * 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
JP6998646B2 (ja) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
CN103102414B (zh) * 2013-02-04 2014-08-27 无锡傲锐东源生物科技有限公司 抗her2蛋白单克隆抗体及其用途
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
CN109966499A (zh) * 2019-04-25 2019-07-05 苏州大学 协同增效的抗乳腺癌转移药物组合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers

Also Published As

Publication number Publication date
WO2000061185A1 (en) 2000-10-19
MXPA01010138A (es) 2003-07-14
HUP0201459A3 (en) 2003-04-28
HUP0201459A2 (en) 2002-09-28
DE60023476T2 (de) 2006-07-06
NZ515337A (en) 2003-10-31
NO20014842D0 (no) 2001-10-04
JP2012136535A (ja) 2012-07-19
EA200101064A1 (ru) 2002-04-25
ES2248070T3 (es) 2006-03-16
DE60023476D1 (de) 2005-12-01
ZA200107771B (en) 2002-09-20
HK1046093B (zh) 2005-10-28
CZ296373B6 (cs) 2006-03-15
CN1350464A (zh) 2002-05-22
CZ20013614A3 (cs) 2002-07-17
NO20014842L (no) 2001-10-04
JP2003512298A (ja) 2003-04-02
TR200102845T2 (tr) 2002-01-21
BR0009647A (pt) 2002-01-08
EP1169059A1 (en) 2002-01-09
CA2368369A1 (en) 2000-10-19
EA006097B1 (ru) 2005-08-25
HU226672B1 (en) 2009-06-29
CN1191859C (zh) 2005-03-09
AU4332700A (en) 2000-11-14
EP1169059B1 (en) 2005-10-26
KR100695383B1 (ko) 2007-03-15
ATE307608T1 (de) 2005-11-15
NO332619B1 (no) 2012-11-19
HK1046093A1 (en) 2002-12-27
US6333348B1 (en) 2001-12-25
CA2368369C (en) 2014-03-25
KR20020007358A (ko) 2002-01-26
DK1169059T3 (da) 2006-02-27
AU777661B2 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
YU13603A (sh) Postupci tretiranja poremećaja povenzanih sa bcl-2 primenom bcl-2 antisens oligomera
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
HK1106736A1 (en) Combination therapy comprising anti-cd20 and anti-cd40 antibodies for the treatment of b cell-related cancers
PT1165108E (pt) Utilizacao de um extracto de serenoa repens para o fabrico de um medicamento destinado ao tratamento do cancro da prostata.
MX9302038A (es) Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s.
IL155781A0 (en) Effective antitumor treatments
MXPA04004355A (es) Tratamiento de combinacion que comprende zd6474 y un taxano.
MY146533A (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
AU2003217982A8 (en) Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
NZ504928A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
GB0020504D0 (en) Therapeutic method
WO2004056971A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
WO2000006136A3 (en) Therapeutic combination of polyamine with an anticancer agent
IL159770A0 (en) Calcium salts with cytotoxic activity
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
MXPA04009012A (es) Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer.
HK1049608A1 (zh) 丙種球蛋白的投藥治療淋巴瘤
MXPA05008879A (es) Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral.
UA37542A (uk) Спосіб лікування місцево-поширеного раку молочної залози
UA34376A (uk) Спосіб профілактики і корекції психосоматичних розладів у хворих при операціях з приводу рака молочної залози